Russell Investments Group Ltd. raised its stake in Spark Therapeutics Inc (NASDAQ:ONCE) by 334.8% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 109,698 shares of the biotechnology company’s stock after buying an additional 84,470 shares during the period. Russell Investments Group Ltd. owned about 0.30% of Spark Therapeutics worth $9,781,000 at the end of the most recent quarter.
Several other large investors also recently modified their holdings of ONCE. Teachers Advisors LLC increased its holdings in shares of Spark Therapeutics by 1.9% in the 1st quarter. Teachers Advisors LLC now owns 34,534 shares of the biotechnology company’s stock worth $1,842,000 after buying an additional 650 shares during the last quarter. Schwab Charles Investment Management Inc. increased its holdings in shares of Spark Therapeutics by 9.5% in the 1st quarter. Schwab Charles Investment Management Inc. now owns 87,751 shares of the biotechnology company’s stock worth $4,681,000 after buying an additional 7,605 shares during the last quarter. C WorldWide Group Holding A S increased its holdings in shares of Spark Therapeutics by 16.6% in the 2nd quarter. C WorldWide Group Holding A S now owns 52,281 shares of the biotechnology company’s stock worth $3,123,000 after buying an additional 7,449 shares during the last quarter. DekaBank Deutsche Girozentrale bought a new position in shares of Spark Therapeutics in the 2nd quarter worth $829,000. Finally, Rhumbline Advisers increased its holdings in shares of Spark Therapeutics by 16.0% in the 2nd quarter. Rhumbline Advisers now owns 26,278 shares of the biotechnology company’s stock worth $1,570,000 after buying an additional 3,626 shares during the last quarter. 94.94% of the stock is currently owned by hedge funds and other institutional investors.
A number of equities analysts have recently commented on the stock. Chardan Capital raised shares of Spark Therapeutics from a “neutral” rating to a “buy” rating and increased their price target for the stock from $60.00 to $100.00 in a report on Tuesday, August 8th. SunTrust Banks set a $101.00 price objective on shares of Spark Therapeutics and gave the company a “buy” rating in a research note on Monday, October 16th. Evercore ISI began coverage on shares of Spark Therapeutics in a research note on Wednesday, August 16th. They issued an “in-line” rating and a $83.00 price objective for the company. BidaskClub raised shares of Spark Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, August 26th. Finally, Cantor Fitzgerald reaffirmed a “buy” rating on shares of Spark Therapeutics in a research note on Friday, August 25th. Three research analysts have rated the stock with a sell rating, one has given a hold rating and eighteen have given a buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $90.36.
Spark Therapeutics (NASDAQ:ONCE) last announced its quarterly earnings results on Tuesday, November 7th. The biotechnology company reported ($1.90) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.79) by ($0.11). The firm had revenue of $1.90 million for the quarter, compared to analysts’ expectations of $1.40 million. Spark Therapeutics had a negative net margin of 1,090.11% and a negative return on equity of 60.01%. The company’s quarterly revenue was up 45.8% on a year-over-year basis. During the same period in the previous year, the company earned ($1.07) EPS. equities analysts forecast that Spark Therapeutics Inc will post -7.6 earnings per share for the current fiscal year.
In other Spark Therapeutics news, CEO Jeffrey D. Marrazzo sold 20,000 shares of the stock in a transaction on Monday, November 13th. The shares were sold at an average price of $71.54, for a total transaction of $1,430,800.00. Following the completion of the sale, the chief executive officer now owns 250,000 shares of the company’s stock, valued at approximately $17,885,000. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Barge Joseph La sold 5,500 shares of the stock in a transaction on Monday, November 13th. The shares were sold at an average price of $71.44, for a total transaction of $392,920.00. Following the sale, the insider now directly owns 8,146 shares of the company’s stock, valued at approximately $581,950.24. The disclosure for this sale can be found here. Insiders have sold a total of 1,077,809 shares of company stock valued at $90,559,445 in the last three months. 7.30% of the stock is currently owned by corporate insiders.
About Spark Therapeutics
Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.
Want to see what other hedge funds are holding ONCE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Spark Therapeutics Inc (NASDAQ:ONCE).
Receive News & Ratings for Spark Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.